title: Eicosapentaenoic acid metabolism in brain microvessel endothelium: effect on prostaglandin formation.
abstract: Mouse brain microvessel endothelial cells convert eicosapentaenoic acid (EPA) to prostaglandin (PG) E3, PGI3, and several hydroxy fatty acid derivatives. Similar types of products are formed by these microvessel endothelial cells from arachidonic acid. The formation of PGI2 and PGE2 is reduced, however, when the brain microvessel endothelial cultures are incubated initially with EPA. Exposure to linolenic or docosahexaenoic acid also decreased the capacity of these microvessel endothelial cells to form PGI2 and PGE2, but the reductions were smaller than those produced by EPA. Like the endothelial cultures, intact mouse brain microvessels convert EPA into eicosanoids, and incubation with EPA reduces the subsequent capacity of the microvessels to produce PGI2 and PGE2. Brain microvessel endothelial cells took up less EPA than arachidonic acid, primarily due to lesser incorporation into the inositol, ethanolamine, and serine glycerophospholipids. By contrast, considerably more EPA than arachidonic acid was incorporated into triglycerides. These findings suggest that the microvessel endothelium may be a site of conversion of EPA to eicosanoids in the brain and that EPA availability can influence the amount of dienoic prostaglandins released by the brain microvasculature. Furthermore, the substantial incorporation of EPA into triglyceride suggests that this neutral lipid may play an important role in the processing and metabolism of EPA in brain microvessels.
authors.affiliation: Department of Biochemistry, University of Iowa, Iowa City 52242.
authors.forename: N R
authors.initials: NR
authors.lastname: Yerram
authors.forename: S A
authors.initials: SA
authors.lastname: Moore
authors.forename: A A
authors.initials: AA
authors.lastname: Spector
mesh_terms: D000818:Animals; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000378:metabolism; D001921:Brain / Q000098:blood supply*; D000001:Calcimycin / Q000494:pharmacology; D002478:Cells, Cultured; D002851:Chromatography, High Pressure Liquid; D015232:Dinoprostone / Q000096:biosynthesis*; D015118:Eicosapentaenoic Acid / Q000378:metabolism* / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism*; D011464:Epoprostenol / Q000096:biosynthesis*; D005227:Fatty Acids / Q000494:pharmacology; D006801:Humans; D051379:Mice; D008833:Microcirculation; D014471:Umbilical Veins
chemical_list: D001095:Arachidonic Acids; D005227:Fatty Acids; D016718:Arachidonic Acid; D000001:Calcimycin; D015118:Eicosapentaenoic Acid; D011464:Epoprostenol; D015232:Dinoprostone